Tom Snow: The FDA approved our combination therapy for adults with newly diagnosed Multiple Myeloma
Olivier Nataf, Global Head of Oncology at Sanofi, shared a post by Tom Snow on LinkedIn, adding:
“Incredibly exciting news for the Multiple Myeloma community!
Our therapy is now approved in the U.S. in combination with standard-of-care for newly diagnosed people not eligible for transplant.
So proud of the entire team at Sanofi who strives to make a meaningful difference in treatment outcomes for people who live with this difficult-to-treat disease.”
Quoting Tom Snow‘s post:
“Today, the FDA approved our combination therapy for adults with newly diagnosed Multiple Myeloma.
We’re proud to bring this innovative therapy to more people in the multiple myeloma community as we strive to make a meaningful difference for people living with this blood cancer.
Read more about the approval here.”
Source: Olivier Nataf/LinkedIn and Tom Snow/LinkedIn
Tom Snow is the General Manager for US Oncology at Sanofi. Previously, he served as the Global Franchise Head for Neurology and Rare Blood Disorders, leading the strategy for conditions such as multiple sclerosis, Parkinson’s disease, ALS, and Alzheimer’s disease, as well as for hemophilia and immune-mediated hematology. He is also a member of the Board of Directors for the MassBioEd Foundation.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023